Drugs / [18F]JNJ-64511070
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03270579 | Sep 2017 → Feb 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]JNJ-64511070 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03270579 ↗ |
| Modality | Diagnostic / imaging agent | “a AMPA-R associated TARP-γ8 specific PET ligand [18F]JNJ-64511070” PMID 40694102 ↗ Jul 2025 |
| Route | Intravenous | “An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.” NCT03270579 ↗ |